Table 6.
Disease management potential of quercetin via the modulation of various activities.
| Activity | Study Types | Animal/Cell Lines | Dose | Outcomes of the Study | Refs. |
|---|---|---|---|---|---|
| Cardioprotective | In vivo | Rats | 10 mg/kg |
|
[75] |
| In vivo | Rats | 20 mg/kg |
|
[76] | |
| In vivo | Rats | 10 mg/kg |
|
[77] | |
| Renoprotective | In vivo | Mice | 10 g/kg |
|
[80] |
| In vivo | Mice | 5, 10 mg/kg |
|
[81] | |
| Rats | 50 mg/kg |
|
[82] | ||
| In vivo | Rats | 2 mg/kg |
|
[83] | |
| Rats | 100 mg/kg |
|
[85] | ||
| Anti-obesity | In vivo | Rats | 185 mg/kg |
|
[88] |
| Mice | 0.1% (weight/weight) quercetin |
|
[89] | ||
| In vitro | 3T3-L1 preadipocytes | 0, 10, 50, or 100 μM |
|
[90] | |
| In vitro and in vivo | 3T3-L1 & Rats | 75 and 100 μg/mL and 0.72% OPE |
|
[91] | |
| Anti-arthritis | In vivo | Rats | 100 mg/kg |
|
[94] |
| In vitro | Fibroblast-like synoviocytes | 50 nmol/L |
|
[96] | |
| In vitro | Fibroblast-like synoviocytes | 0, 10, 20, or 30 M |
|
[98] | |
| Anti-dermatitis | In vivo | Mice | 50 or 100 mg/kg |
|
[39] |
| In vivo | Mice | 30, 60, and 120 mg/kg |
|
[99] | |
| In vitro, in vivo | HaCaT cells, THP-1, and RAW 264.7, mice | 0.01–1 μM and 1 μM and 10 μM |
|
[102] | |
| Effects in respiratory system | In vivo | Mice | 10 mg/kg |
|
[106] |
| In vitro and in vivo | Rats, NCI-H292 cells |
25 and 50 mg/kg 5, 10, or 20 μM |
|
[108] | |
| In vitro | Human alveolar epithelial cell A549 | 10, 20, and 40 μM |
|
[8] | |
| Role in oral health | In vitro | Human oral keratinocytes | 20 μM |
|
[116] |
| In vitro | hOMK107 cells | 20, 40, and 80 μM |
|
[117] | |
| Wound healing effects | In vivo | Rats | Quercetin gel was 5% with a dose of 20 µg |
|
[126] |
| In vivo | Rats | 10, 20, and 40 mg/mL |
|
[127] | |
| Anti-colitis effects | In vivo | Mice | 50 mg/kg |
|
[129] |
| In vivo | Mice | 500 ppm |
|
[130] | |
| In vivo | Mice | 25, 50, and 100 mg/kg |
|
[131] | |
| Anti-platelet activation | In vivo | Rats | 5 mg/kg |
|
[134] |
| Anti-depressant effects | In vivo | Mice | 50 mg/kg |
|
[152] |
| In vivo | Rats | 60 mg/kg |
|
[154] | |
| Role in reproductive system | In vivo | Rats | 50 mg/kg |
|
[164] |
| In vivo | Rats | 50 mg/Kg |
|
[166] | |
| In vivo | Mice | 5 mg/Kg |
|
[168] | |
| Role in bone health | In vivo | Mice | 0.25% (LQ) or 2.5% quercetin |
|
[171] |
| In vivo | Rats | 15 mg/kg |
|
[173] | |
| In vivo | Rats | 5, 30, and 50 mg/kg |
|
[174] | |
| Radioprotective effects | In vivo | Mice | 100 mg/kg |
|
[179] |
| In vivo | Mice | 20 mg/kg |
|
[180] |